Quarterly sales of the rare disease treatments ‘Soliris (eculizumab)’ and ‘Ultomiris (ravulizumab)’ had risen significantly in Q1 this year. Although sales of Soliris remained similar to last year, sales of Ultomiris, its follow-on drug, soared in the same period. The analysis is that the generation change between the two drugs has neared completion.

According to the market research institution IQVIA on the 12th, sales of Ultomiris in Q1 were KRW 13 billion, up 35% from KRW 9.6 billion in Q1 last year. During the same period, Soliris’s sales slightly fell from KRW 2.8 billion to KRW 2.4 billion.

Soliris is a rare disease treatment indicated for the treatment of ▲ paroxysmal nocturn